CRISPR Therapeutics (NASDAQ:CRSP) Now Covered by Analysts at HC Wainwright

HC Wainwright started coverage on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report released on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $65.00 price target on the stock. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.98) EPS, FY2024 earnings at ($4.83) EPS, Q1 2025 earnings at ($1.11) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($1.03) EPS and FY2025 earnings at ($4.25) EPS.

Several other research analysts also recently commented on CRSP. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Chardan Capital restated a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Barclays lowered their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, December 20th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $77.59.

CRISPR Therapeutics Stock Performance

CRSP opened at $42.22 on Monday. The stock’s 50 day moving average price is $43.20 and its 200-day moving average price is $46.82. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of -14.92 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter in the prior year, the company posted ($1.41) EPS. As a group, analysts predict that CRISPR Therapeutics will post -5.1 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics during the 4th quarter valued at approximately $39,000. Western Pacific Wealth Management LP increased its position in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics in the 3rd quarter worth $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth about $43,000. Finally, Eastern Bank acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at about $70,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.